Jaime Rosenberg

Investigators used national electronic health record data to determine the proportion of American adults who have been tested for HIV.

A phase 1 study demonstrated that pembrolizumab is appropriate for FDA-approved indications and clinical trials among people living with HIV and advanced cancer.

A survey of nearly 300 pharmacy students found that 91% were aware of PrEP and 61% reported high familiarity with PrEP prescription guidelines, but knowledge gaps still remain.

Better rates of overall survival were seen when patients received granulocyte transfusions within 7 days of neutropenic sepsis.

Mutual of Omaha will no longer deny coverage to individuals using PrEP for HIV prevention following allegations of discrimination in 2 separate legal settlements.

People living with HIV are twice as likely to develop cardiovascular disease than noninfected individuals, and are more likely to have incident heart failure than the general population, even after adjustment for demographics and cardiovascular risk factors.

Single-tablet regimens may provide better virologic response and control than multiple-tablet regimens for people living with HIV, likely due to a lower pill burden and, subsequently, better medication adherence, according to the results of a new study.

Study results indicate that patients with HIV are willing to wait at least 19 hours or travel up to 28 miles to see a “nice” provider.

Study results indicate that starting combination antiretroviral therapy early can stave off further neurological damage associated with HIV infection.

Primary care physicians are using an innovative heatmap, customized web-based software, and an extensive survey to reduce the number of new HIV diagnoses and increase viral suppression rates in patients with HIV.